U.S. Dry Eye Syndrome Treatment Market To Reach $3.47 Billion By 2030

U.S. Dry Eye Syndrome Treatment Market Growth & Trends

The U.S. dry eye syndrome treatment market size is anticipated to reach USD 3.47 billion by 2030 and is anticipated to expand at a CAGR of 6.0% during the forecast period, according to a new report by Grand View Research, Inc. Market growth in the U.S. for dry eye disease (DED) has been significantly influenced by its high prevalence. By 2024, this condition has shown notable age-related increases, particularly among women, with around 6.8% of the adult population diagnosed.

The substantial patient base has highlighted the urgent need for effective treatment options, leading to a burgeoning market for companies catering to this demographic’s needs. The aging population, particularly those aged 65 and older, has significantly contributed to the rising incidence of DED. This demographic shift has created increased demand for treatment as pharmaceutical companies and healthcare providers have adapted their strategies.

In 2023 and 2024, heightened awareness of DED, linked to increased screen time from digital devices, has further surged demand. Innovations in treatment options, including prescription medications and over-the-counter (OTC) products, have improved diagnosis rates. By 2025, new therapies such as Reproxalap, IC 265, and Acoltremon are anticipated to enhance relief and drive future market expansion.

 Request a free sample copy or view report summary: U.S. Dry Eye Syndrome Treatment Market Report

U.S. Dry Eye Syndrome Treatment Market Report Highlights

• The growing prevalence of DED in approximately 20 million Americans highlights urgent treatment needs and market opportunities for companies.

• Based on type, evaporative dry eye syndrome dominated the type segment, accounting for 82.5% of the total revenue share in 2024.

• Based on drugs, Cequa is projected to grow at the fastest CAGR of 27.0% over the forecast period.

• Based on product, cyclosporine led the market in 2024, demonstrating clinical efficacy in treating dry eye syndrome, significantly increasing tear production and reducing inflammation.

• Eye drops, especially artificial tears, offer rapid relief from dry eye symptoms by lubricating the eyes and mimicking natural tears, thus dominating the dosage form segment in 2024.

• Based on prescription, OTC drugs are expected to register the fastest CAGR of 6.5% over the forecast period.

• Retail pharmacies dominated the market, with online pharmacies exhibiting the fastest CAGR of 6.6% over the forecast period.

• In August 2024, OCuSOFT launched Retaine Allergy prescription-strength antihistamine drops in the U.S., enhancing its product line focused on dry eye solutions and allergy relief.

U.S. Dry Eye Syndrome Treatment Market Report Segmentation

Grand View Research has segmented the U.S. dry eye syndrome treatment market on the basis oftype, drugs, product, dosage form, sales channel, distribution channel, and region:

U.S. Dry Eye Syndrome Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Evaporative

• Aqueous Deficient

U.S. Dry Eye Syndrome Treatment Drugs Outlook (Revenue, USD Million, 2018 - 2030)

• Xiidra

• Restasis

• Cequa

• Tyrvaya

• Eysuvis

• Others

U.S. Dry Eye Syndrome Treatment Product Outlook (Revenue, USD Million, 2018 - 2030)

• Artificial Tears

• Cyclosporine

• Topical Corticosteroids

• Punctal Plugs

  • Removable

  • Dissolvable

• Oral Omega Supplements

• Others

U.S. Dry Eye Syndrome Treatment Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

• Eye Drops / Solutions

• Ointments and Gels

• Capsules & Tablets

• Others

U.S. Dry Eye Syndrome Treatment Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• OTC

U.S. Dry Eye Syndrome Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Pharmacies

• Hospital Pharmacies

• Online Pharmacies

List of Key Players in the U.S. Dry Eye Syndrome Treatment Market

• Novartis AG

• AbbVie Inc.

• Sun Pharmaceutical Industries Ltd.

• Janssen Pharmaceutica (Pty.) Ltd.

• OASIS Medical, Inc.

• Viatris Inc.

• Bausch Health Companies Inc.

• Santen Pharmaceutical Co., Ltd.